All News

RheumNow Podcast square

RheumNow Podcast – Modern Treatment of RA Pregnancy (6.25.2021)

Jack Cush, MD

Dr. Jack Cush reviews this week’s news and journal reports featured on RheumNow.com.

Read Article
unhappy%20patient.jpg

How do we personalize psoriatic arthritis treatment?

Robert Chao, MD

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?

Read Article
EULAR,Podcast,2021

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Read Article
grappa sign treatment recommendations

New GRAPPA 2021 PsO and PsA Treatment Recommendations

Rachel Tate, DO

The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021.

Read Article
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX) -Tx . (TP)1: SEC 75/100 mg till wk 12 -TP2: cont SEC or switch to PBO till wk 104 ⭐️SEC efficacious on JIA ACR30/70 ⭐️74% w/ resolution of enthes ⭐️Median T2flare in PBO in TP2 = 453d LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we
Eric Dein ejdein1 ( View Tweet)
JUNIPERA - secukinumab in enthesitis related arthritis and juvenile PsA ⭐️achieved JIA ACR response compared to placebo ⭐️⬇️time to flare ⭐️75% with resolution of enthesitis ⭐️0 deaths, AE - minor infections, GI issues, headache Abs#LB0004 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

SPIRIT-P1&P2 studies showed IXE effective in treating axPsA. When do you consider IL17i in your treatment algorithm in axPsA (as the predominant domain?) Poster #POS1045 #EULAR2021 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

SPIRIT-P1&P2: IXE is effective in⬇️axial symptoms & improving QoL in active PsA pts with axial involvement. Abstract #POS1045 #EULAR2021 @RheumNow https://t.co/GC78Lmp9cH https://t.co/WfaUqIRrY6

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
PREVENT: SEC 150 mg showed durable improvement in nr-axSpA through 2 yrs, 438 pts. No new or unexpected safety signals. Poster #POS0900 #EULAR2021 @RheumNow https://t.co/NU1EO9zktn https://t.co/LP3hkZodhi

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal. #LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI
Aurelie Najm AurelieRheumo ( View Tweet)
2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.

Eric Dein ejdein1 ( View Tweet)

IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy? ⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo ⭐️no difference in pain score Abs#POS0022 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×